ImpediMed

ImpediMed Market Cap per Employee

The Market Cap per Employee of ImpediMed (IPD.AX) as of Nov 12, 2026 is 471,650.60 AUD. In the previous year, Market Cap per Employee was 471,650.60 AUD — a change of 0.00% (lower).

Market Cap per Employee

471,650.60AUD

YoY

0.00%

Last updated:

Market Cap per Employee of ImpediMed is 2026 471,650.60 AUD. Market Cap per Employee of ImpediMed was 2025 471,650.60 AUD. It decreases by 0.00% lower compared to the previous year.

The ImpediMed Market Cap per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Cap per Employee
Date
Market Cap per Employee
Jan 1, 2019
471,650.60 AUD
Jan 1, 2020
471,650.60 AUD
Jan 1, 2021
471,650.60 AUD
Jan 1, 2022
471,650.60 AUD
Jan 1, 2023
471,650.60 AUD
Jan 1, 2024
471,650.60 AUD
Jan 1, 2025
471,650.60 AUD
Jan 1, 2026
471,650.60 AUD
The ImpediMed Market Cap per Employee history
YEARMarket Cap per EmployeeYoY
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD0.00%
471,650.60AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Market Cap per Employee of ImpediMed is 471,650.60 AUD in 2026.

Market Cap per Employee of ImpediMed changed from 471,650.60 AUD to 471,650.60 AUD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Market Cap per Employee ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Market cap per employee shows the market value attributed to each employee. Technology companies typically have higher values due to intellectual capital.

Market Cap per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Market Cap per Employee's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — ImpediMed

All Key Metrics — ImpediMed